Jonathas Alves de Melo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonathas Alves de Melo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Cláudia Jassica Gonçalves Moreno
Global Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation Towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, 1349-008 Lisboa, Portugal
1 shared publication - Johny Wysllas de Freitas Oliveira
Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Centre of Health Sciences, Federal University of Rio Grande do Norte-UFRN, Natal, RN, Brazilhttps://ror.org/04wn09761https://www.isni.org/isni
1 shared publication - Joice Castelo Branco Santos
Graduate Program in Microbial Biology, CEUMA University, Rua Josué Montello, 1—Renascença II, São Luís 65075-120, MA, Brazil
1 shared publication - L. Mario Amzel
Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, USA
1 shared publication - Marcelo Sousa Silva
Postgraduate Programme in Pharmaceutical Sciences, Federal University of Rio Grande do Norte
1 shared publication - Sandra Beatriz Gabelli
Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, USA
1 shared publication
Latest Publications
- Open Access
Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs
Neglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis.
Open AccessBisphosphonate-Based Molecules as Potential New Antiparasitic Drugs
Neglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis.